A Phase 1, Randomized, Double-Blind, Active Comparator Controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Novel Pneumococcal Vaccine in Children
Latest Information Update: 02 Mar 2026
At a glance
- Drugs V 118 (Primary) ; Pneumococcal 20-valent conjugate vaccine
- Indications Pneumococcal infections
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 21 Jan 2026 Status changed from not yet recruiting to recruiting.
- 31 Dec 2025 New trial record